Immunovia
ISIN: SE0006091997 | Ticker: IMMNOV | LEI: 549300KHWL6KK1XGUO81
Country: Sweden
Immunovia AB is a diagnostic company that is developing and commercializing highly accurate blood tests for the early detection of cancer and autoimmune diseases based on Immunovia’s proprietary test platform called IMMray™. Tests are based on antibody biomarker microarray analysis using advanced machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a unique “disease biomarker signature”.
The company was founded in 2007, based on cancer studies and ground-breaking research in the Department of Immuntechnology at Lund University and CREATE Health Cancer Center, Sweden.
The first product, IMMray™ PanCan-d, is undergoing clinical evaluation in some of the world’s largest clinical studies for high risk groups in pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1.
2007
HeadquartersScheelevägen 2, 22381 Lund – Sweden
| Line item in (sek) | 01.01.2019 | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|---|
| Assets | N/A | N/A | N/A | 493,809,000.00 | 300,589,000.00 |
| Noncurrent Assets | N/A | N/A | N/A | 196,707,000.00 | 184,974,000.00 |
| Property Plant And Equipment | N/A | N/A | N/A | 46,527,000.00 | 47,877,000.00 |
| Intangible Assets Other Than Goodwill | N/A | N/A | N/A | 122,492,000.00 | 110,073,000.00 |
| Copyrights Patents And Other Industrial Property Rights Service And Operating Rights | N/A | N/A | N/A | 24,655,000.00 | 23,524,000.00 |
| Other Noncurrent Financial Assets | N/A | N/A | N/A | 3,033,000.00 | 3,500,000.00 |
| Current Assets | N/A | N/A | N/A | 297,102,000.00 | 115,615,000.00 |
| Inventories | N/A | N/A | N/A | 2,150,000.00 | 2,016,000.00 |
| Trade And Other Current Receivables | N/A | N/A | N/A | 9,696,000.00 | 9,574,000.00 |
| Current Trade Receivables | N/A | N/A | N/A | 72,000.00 | 253,000.00 |
| Current Prepaid Expenses | N/A | N/A | N/A | 3,453,000.00 | 4,348,000.00 |
| Other Current Nonfinancial Assets | N/A | N/A | N/A | 4,021,000.00 | 2,957,000.00 |
| Cash and cash equivalents | 468,462,000.00 | 287,406,000.00 | N/A | 287,406,000.00 | 106,041,000.00 |
| Equity And Liabilities | N/A | N/A | N/A | 493,809,000.00 | 300,589,000.00 |
| Equity | N/A | N/A | 599,403,000.00 | 433,903,000.00 | 243,803,000.00 |
| Issued Capital | N/A | N/A | N/A | 1,132,000.00 | 1,132,000.00 |
| Retained Earnings | N/A | N/A | N/A | -581,300,000.00 | -749,392,000.00 |
| Share Premium | N/A | N/A | N/A | 1,015,730,000.00 | 1,016,369,000.00 |
| Other Reserves | N/A | N/A | N/A | -1,658,000.00 | -24,306,000.00 |
| Additional Paidin Capital | N/A | N/A | N/A | 440,000.00 | 639,000.00 |
| Noncurrent Liabilities | N/A | N/A | N/A | 27,156,000.00 | 32,700,000.00 |
| Current Liabilities | N/A | N/A | N/A | 32,750,000.00 | 24,086,000.00 |
| Line item in (sek) | 01.01.2020/ 01.01.2022 |
01.01.2021/ 01.01.2022 |
01.01.2021/ 01.01.2023 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|---|
| Revenue | N/A | 956,000.00 | N/A | 1,204,000.00 |
| Revenue From Royalties | N/A | 844,000.00 | N/A | 1,145,000.00 |
| Other Work Performed By Entity And Capitalised | N/A | -18,502,000.00 | N/A | 0.00 |
| Raw Materials And Consumables Used | N/A | -3,533,000.00 | N/A | -4,211,000.00 |
| Employee Benefits Expense | N/A | -79,487,000.00 | N/A | -85,222,000.00 |
| Depreciation And Amortisation Expense | N/A | -19,063,000.00 | N/A | -24,913,000.00 |
| Other Expense By Nature | N/A | -82,607,000.00 | N/A | -77,749,000.00 |
| Profit Loss From Operating Activities | N/A | -166,628,000.00 | N/A | -191,150,000.00 |
| Finance Income | N/A | 14,459,000.00 | N/A | 41,259,000.00 |
| Finance Costs | N/A | -3,797,000.00 | N/A | -18,201,000.00 |
| Profit Loss Before Tax | N/A | -155,966,000.00 | N/A | -168,092,000.00 |
| Income Tax Expense Continuing Operations | N/A | 0.00 | N/A | 0.00 |
| Profit (loss) | -165,940,000.00 | -155,966,000.00 | -190,740,000.00 | -168,092,000.00 |
| Line item in (sek) | 01.01.2019 | 01.01.2020 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Profit (loss) | N/A | N/A | -155,966,000.00 | -168,092,000.00 |
| Adjustments For Reconcile Profit Loss | N/A | N/A | 20,048,000.00 | 23,471,000.00 |
| Adjustments For Reconcile Profit Loss | N/A | N/A | 20,048,000.00 | 23,471,000.00 |
| Cash Flows From Used In Operations | N/A | N/A | -147,310,000.00 | -168,428,000.00 |
| Interest Received Classified As Operating Activities | N/A | N/A | 711,000.00 | 745,000.00 |
| Cash Flows From Used In Operating Activities | N/A | N/A | -152,648,000.00 | -175,582,000.00 |
| Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities | N/A | N/A | 358,000.00 | 0.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | N/A | N/A | -3,101,000.00 | -1,256,000.00 |
| Purchase Of Intangible Assets Classified As Investing Activities | N/A | N/A | -21,083,000.00 | -368,000.00 |
| Cash Flows From Used In Investing Activities | N/A | N/A | -23,826,000.00 | -1,624,000.00 |
| Proceeds From Issuing Other Equity Instruments | N/A | N/A | 440,000.00 | 639,000.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | N/A | N/A | -5,709,000.00 | -5,746,000.00 |
| Interest Paid Classified As Financing Activities | N/A | N/A | -1,441,000.00 | -1,494,000.00 |
| Income Taxes Paid Refund Classified As Financing Activities | N/A | N/A | 0.00 | 0.00 |
| Cash Flows From Used In Financing Activities | N/A | N/A | -5,269,000.00 | -5,107,000.00 |
| Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | N/A | N/A | -181,743,000.00 | -182,313,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | N/A | 687,000.00 | 948,000.00 |
| Cash and cash equivalents | 468,462,000.00 | 287,406,000.00 | 287,406,000.00 | 106,041,000.00 |
Please note that some sums might not add up.
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 03.01.24 | michael Lofman | Other | Sell | SEK 1,292,570.40 |
| 07.06.23 | Jeffrey Borcherding | Other | Buy | USD 61,810.00 |
| 06.04.23 | Hans Johansson | Other | Buy | SEK 99,990.80 |
| 28.03.23 | Martin Moeller | Other | Other | SEK 9,433.60 |
| 15.11.22 | Philipp Mathieu | Other | Buy | SEK 297,000.00 |
| 24.05.22 | Jeffrey Borcherding | Other | Buy | SEK 150,000.00 |
| 22.02.22 | Peter Andersen | Other | Buy | SEK 186,000.00 |
| 02.09.21 | Martin Moeller | Other | Buy | SEK 141,292.80 |
| 28.05.21 | Patrik Dahlen | Other | Buy | SEK 675,984.40 |
| 07.05.21 | Peter Andersen | Other | Buy | SEK 297,570.00 |
SE0006091997
LEI549300KHWL6KK1XGUO81
SectorHealth Care Equipment & Services
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.